Status | Study |
Active, not recruiting |
Study Name: A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome Condition: Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome Date: 2016-03-07 Interventions: Drug: KRN23 Doses may be titrated to achieve the target peak serum phosphorus range |
Recruiting |
Study Name: Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors Causing Oncogenic Osteomalacia Condition: Tumor Induced Oncogenic Osteomalacia Date: 2015-01-05 |
Active, not recruiting |
Study Name: Study of KRN23 in Adult Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS) Condition: Tumor Induced Osteomalacia (TIO) Epidermal Nevus Syndrome (ENS) Date: 2014-11-24 Interventions: Drug: KRN23 KRN23 is a recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that b |
Terminated |
Study Name: Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets) Condition: Osteomalacia Date: 2012-12-11 Interventions: Drug: Osteomalacia |
Recruiting |
Study Name: Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia Condition: Hypophosphatemia Date: 2012-08-05 |
Recruiting |
Study Name: 68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia Condition: Oncogenic Osteomalacia Mesenchymal Tumor Date: 2012-01-29 Interventions: Drug: 68Ga-DOTATATE Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. T |
Completed |
Study Name: Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia Condition: Osteomalacia Neoplasms Date: 2004-12-17 |